Cargando…
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
Immune checkpoint blockers have dramatically improved the chances of survival in patients with metastatic cancer, but only a subset of the patients respond to treatment. Search for novel targets that can improve the responder rates and overcome the limitations of adverse events commonly seen with co...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472042/ https://www.ncbi.nlm.nih.gov/pubmed/34572463 http://dx.doi.org/10.3390/biomedicines9091277 |